(Reuters) - Amgen Inc's version of AbbVie Inc's Humira arthritis drug, the world's top-selling medicine, appears similar in potency and safety to the original product, U.S. Food and Drug ...
The FDA's push for lower-cost medicines looks good on paper, but the patent office under President Trump may be going in the ...
About 1.5 million Americans suffer from rheumatoid arthritis, a chronic disease in which the immune system attacks healthy cells, typically around the joints, causing swelling and deformity. Generally ...
Dr. Beth Jonas answers the question: 'Anti-TNF Meds For Rheumatoid Arthritis?' — -- Question: What are anti-tumor necrosis factor (anti-TNF) medications and how are they used to treat rheumatoid ...
LONDON, March 15 (Reuters) - Abbott Laboratories' drug Humira and Enbrel, from Pfizer and Amgen , should be the first choices for treating patients with psoriatic arthritis, Britain's ...
AbbVie and its longtime blockbuster arthritis drug Humira are now front and center in the Outcome Health trial. Outcome Health was a high-flying Chicago company that made headlines when it raised $488 ...
Shares of the immunology juggernaut AbbVie (NYSE: ABBV) were down by 4% on sky-high volume as of 11 a.m. ET Thursday. That's equivalent to a $7 billion drop in market capitalization. What's spooking ...
Dublin, June 21, 2019 (GLOBE NEWSWIRE) -- The "Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2027" report has been added to ResearchAndMarkets.com's offering. "Plaque Psoriasis: Global ...
Today, Coherus and Mark Cuban announced a partnership to launch an ultra-low-priced Humira biosimilar. This steep discount might have negative consequences for both AbbVie and Amgen later on this year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback